Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitamin D Deficiency | 9 | 2022 | 1389 | 2.930 |
Why?
|
Vitamin D | 13 | 2022 | 3312 | 2.160 |
Why?
|
Cholecalciferol | 4 | 2022 | 558 | 2.020 |
Why?
|
Ehlers-Danlos Syndrome | 2 | 2023 | 94 | 1.420 |
Why?
|
Marfan Syndrome | 2 | 2023 | 237 | 1.330 |
Why?
|
Bone Diseases, Metabolic | 3 | 2023 | 411 | 1.320 |
Why?
|
Dietary Supplements | 7 | 2022 | 3446 | 1.310 |
Why?
|
Bone Density | 6 | 2024 | 3573 | 1.160 |
Why?
|
Osteoporosis | 4 | 2024 | 1604 | 1.090 |
Why?
|
Arthritis, Rheumatoid | 6 | 2023 | 3778 | 1.070 |
Why?
|
Clostridium Infections | 2 | 2024 | 562 | 1.050 |
Why?
|
Vitamins | 7 | 2022 | 1639 | 0.990 |
Why?
|
Femur Neck | 2 | 2023 | 318 | 0.930 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2024 | 164 | 0.910 |
Why?
|
Renal Insufficiency | 2 | 2021 | 812 | 0.910 |
Why?
|
Calcifediol | 2 | 2022 | 160 | 0.900 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2025 | 320 | 0.860 |
Why?
|
Loeys-Dietz Syndrome | 1 | 2023 | 40 | 0.830 |
Why?
|
Hypercalcemia | 1 | 2025 | 424 | 0.780 |
Why?
|
Osteoporotic Fractures | 2 | 2023 | 417 | 0.740 |
Why?
|
Thalassemia | 1 | 2021 | 267 | 0.730 |
Why?
|
Ergocalciferols | 1 | 2021 | 110 | 0.720 |
Why?
|
Malabsorption Syndromes | 1 | 2021 | 135 | 0.720 |
Why?
|
Hyperthyroidism | 1 | 2022 | 292 | 0.680 |
Why?
|
Connective Tissue Diseases | 1 | 2023 | 285 | 0.670 |
Why?
|
Osteogenesis Imperfecta | 1 | 2020 | 81 | 0.670 |
Why?
|
beta-Thalassemia | 1 | 2021 | 234 | 0.640 |
Why?
|
Uric Acid | 3 | 2020 | 805 | 0.630 |
Why?
|
Arthritis, Psoriatic | 1 | 2022 | 219 | 0.630 |
Why?
|
Fractures, Bone | 2 | 2021 | 2062 | 0.620 |
Why?
|
Glucuronidase | 1 | 2020 | 205 | 0.620 |
Why?
|
Femoral Fractures | 1 | 2022 | 376 | 0.610 |
Why?
|
Parathyroid Hormone | 3 | 2023 | 1804 | 0.610 |
Why?
|
Hospital Costs | 1 | 2024 | 956 | 0.610 |
Why?
|
Neurofibromatosis 1 | 1 | 2023 | 561 | 0.590 |
Why?
|
Databases, Genetic | 1 | 2025 | 1758 | 0.580 |
Why?
|
Odds Ratio | 11 | 2023 | 9660 | 0.560 |
Why?
|
Hospital Mortality | 4 | 2024 | 5345 | 0.560 |
Why?
|
Hypothyroidism | 1 | 2022 | 667 | 0.550 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 317 | 0.530 |
Why?
|
Thailand | 4 | 2024 | 288 | 0.520 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2021 | 2160 | 0.520 |
Why?
|
Spinal Fractures | 1 | 2022 | 710 | 0.480 |
Why?
|
Bone Density Conservation Agents | 1 | 2022 | 797 | 0.480 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.470 |
Why?
|
Rheumatic Diseases | 1 | 2021 | 659 | 0.460 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 1959 | 0.450 |
Why?
|
Fibroblast Growth Factors | 1 | 2019 | 873 | 0.430 |
Why?
|
Humans | 76 | 2025 | 767040 | 0.420 |
Why?
|
Asthma | 3 | 2021 | 6268 | 0.420 |
Why?
|
Psoriasis | 1 | 2021 | 925 | 0.420 |
Why?
|
Hyperglycemia | 1 | 2021 | 1388 | 0.400 |
Why?
|
Acute Kidney Injury | 2 | 2021 | 1946 | 0.390 |
Why?
|
Cohort Studies | 13 | 2023 | 41718 | 0.380 |
Why?
|
Irritable Bowel Syndrome | 3 | 2022 | 454 | 0.370 |
Why?
|
Length of Stay | 1 | 2024 | 6489 | 0.360 |
Why?
|
Absorptiometry, Photon | 4 | 2024 | 1757 | 0.350 |
Why?
|
Dementia | 2 | 2021 | 2741 | 0.330 |
Why?
|
Endocarditis, Bacterial | 2 | 2023 | 436 | 0.320 |
Why?
|
Endocarditis | 2 | 2023 | 352 | 0.320 |
Why?
|
Administration, Oral | 4 | 2021 | 4026 | 0.320 |
Why?
|
Body Mass Index | 6 | 2024 | 13048 | 0.310 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12250 | 0.300 |
Why?
|
Parkinson Disease | 1 | 2022 | 2886 | 0.290 |
Why?
|
Risk Factors | 24 | 2024 | 74886 | 0.290 |
Why?
|
Risk Assessment | 7 | 2023 | 24299 | 0.280 |
Why?
|
Prevalence | 8 | 2024 | 15851 | 0.270 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2299 | 0.260 |
Why?
|
Lumbar Vertebrae | 3 | 2023 | 1885 | 0.240 |
Why?
|
Klebsiella oxytoca | 1 | 2024 | 7 | 0.230 |
Why?
|
Philadelphia Chromosome | 2 | 2023 | 119 | 0.230 |
Why?
|
Hospitalization | 2 | 2021 | 10815 | 0.230 |
Why?
|
Pandemics | 2 | 2021 | 8736 | 0.220 |
Why?
|
Dermatitis, Atopic | 2 | 2021 | 734 | 0.220 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2024 | 122 | 0.210 |
Why?
|
Hypocalcemia | 1 | 2025 | 205 | 0.210 |
Why?
|
Case-Control Studies | 5 | 2021 | 22254 | 0.210 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 1559 | 0.210 |
Why?
|
Double-Blind Method | 3 | 2022 | 12451 | 0.210 |
Why?
|
Enterobacteriaceae | 1 | 2024 | 161 | 0.210 |
Why?
|
Klebsiella Infections | 1 | 2024 | 146 | 0.210 |
Why?
|
Hepatitis C, Chronic | 2 | 2022 | 1032 | 0.210 |
Why?
|
Enterobacteriaceae Infections | 1 | 2024 | 190 | 0.200 |
Why?
|
Parathyroidectomy | 1 | 2024 | 244 | 0.200 |
Why?
|
Bipolar Disorder | 1 | 2019 | 5130 | 0.200 |
Why?
|
Minerals | 1 | 2023 | 279 | 0.190 |
Why?
|
Colitis, Ischemic | 1 | 2021 | 32 | 0.190 |
Why?
|
Middle Aged | 13 | 2024 | 223233 | 0.190 |
Why?
|
Adult | 15 | 2024 | 223317 | 0.190 |
Why?
|
Ventricular Premature Complexes | 1 | 2022 | 112 | 0.190 |
Why?
|
Intubation | 1 | 2021 | 140 | 0.180 |
Why?
|
Connective Tissue | 1 | 2023 | 425 | 0.180 |
Why?
|
Half-Life | 1 | 2021 | 648 | 0.170 |
Why?
|
Aged | 12 | 2024 | 171319 | 0.170 |
Why?
|
Vitamin D-Binding Protein | 1 | 2021 | 130 | 0.170 |
Why?
|
Receptors, Calcitriol | 1 | 2022 | 361 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13491 | 0.170 |
Why?
|
Sunlight | 1 | 2021 | 337 | 0.170 |
Why?
|
Anthropometry | 1 | 2024 | 1345 | 0.170 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2023 | 399 | 0.160 |
Why?
|
Incidence | 7 | 2023 | 21526 | 0.160 |
Why?
|
Substance Abuse, Intravenous | 1 | 2023 | 530 | 0.160 |
Why?
|
Spondylitis, Ankylosing | 1 | 2020 | 158 | 0.160 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 1 | 2020 | 163 | 0.150 |
Why?
|
Immunoenzyme Techniques | 1 | 2021 | 1697 | 0.150 |
Why?
|
Age Distribution | 1 | 2024 | 2870 | 0.150 |
Why?
|
Myasthenia Gravis | 1 | 2021 | 214 | 0.150 |
Why?
|
Genetic Variation | 2 | 2025 | 6611 | 0.150 |
Why?
|
Female | 19 | 2024 | 396660 | 0.150 |
Why?
|
Boston | 2 | 2021 | 9360 | 0.150 |
Why?
|
Atrial Flutter | 1 | 2020 | 253 | 0.150 |
Why?
|
Immunoassay | 1 | 2021 | 744 | 0.150 |
Why?
|
Epidemics | 1 | 2023 | 516 | 0.150 |
Why?
|
Obesity | 4 | 2024 | 13085 | 0.150 |
Why?
|
Atrial Fibrillation | 3 | 2022 | 5180 | 0.140 |
Why?
|
Microbial Sensitivity Tests | 1 | 2024 | 1969 | 0.140 |
Why?
|
Tachycardia, Supraventricular | 1 | 2020 | 272 | 0.140 |
Why?
|
Diphosphonates | 1 | 2022 | 633 | 0.140 |
Why?
|
Male | 15 | 2024 | 364203 | 0.140 |
Why?
|
Area Under Curve | 1 | 2021 | 1639 | 0.140 |
Why?
|
Zinc | 1 | 2021 | 675 | 0.140 |
Why?
|
Adiposity | 2 | 2024 | 1894 | 0.140 |
Why?
|
Vitamin K | 1 | 2019 | 314 | 0.140 |
Why?
|
Rare Diseases | 1 | 2022 | 630 | 0.140 |
Why?
|
Blood Glucose | 2 | 2022 | 6421 | 0.140 |
Why?
|
Metabolic Networks and Pathways | 1 | 2021 | 800 | 0.140 |
Why?
|
Hepatitis B, Chronic | 1 | 2021 | 413 | 0.140 |
Why?
|
Hyperuricemia | 1 | 2019 | 221 | 0.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 3249 | 0.130 |
Why?
|
Independent Living | 1 | 2021 | 584 | 0.130 |
Why?
|
Immune System | 1 | 2021 | 799 | 0.130 |
Why?
|
Hepatitis B | 1 | 2021 | 710 | 0.130 |
Why?
|
Morbidity | 1 | 2021 | 1754 | 0.120 |
Why?
|
Cross Infection | 1 | 2024 | 1426 | 0.120 |
Why?
|
Endometriosis | 1 | 2023 | 873 | 0.120 |
Why?
|
Gastroesophageal Reflux | 1 | 2023 | 834 | 0.120 |
Why?
|
Cross-Over Studies | 1 | 2021 | 2105 | 0.120 |
Why?
|
Stroke | 3 | 2023 | 9746 | 0.120 |
Why?
|
Body Composition | 1 | 2024 | 2454 | 0.120 |
Why?
|
Retrospective Studies | 9 | 2023 | 81659 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5716 | 0.110 |
Why?
|
Prediabetic State | 1 | 2019 | 547 | 0.110 |
Why?
|
Cause of Death | 2 | 2024 | 3717 | 0.110 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1854 | 0.110 |
Why?
|
Urban Population | 1 | 2021 | 2044 | 0.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1433 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15925 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2023 | 2131 | 0.100 |
Why?
|
Nutritional Status | 1 | 2020 | 1628 | 0.100 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59548 | 0.100 |
Why?
|
Intensive Care Units | 2 | 2024 | 3797 | 0.090 |
Why?
|
Hepatitis C | 1 | 2022 | 1594 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2022 | 1661 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 1481 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10748 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2531 | 0.090 |
Why?
|
Thyroid Neoplasms | 1 | 2024 | 2355 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 3049 | 0.090 |
Why?
|
Metabolomics | 1 | 2020 | 1675 | 0.090 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2019 | 1337 | 0.090 |
Why?
|
Migraine Disorders | 1 | 2022 | 1712 | 0.080 |
Why?
|
Bone and Bones | 1 | 2019 | 2587 | 0.080 |
Why?
|
Bacteria | 1 | 2020 | 2212 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 2021 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5693 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2909 | 0.080 |
Why?
|
Pilot Projects | 1 | 2021 | 8732 | 0.070 |
Why?
|
Genotype | 1 | 2022 | 13035 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3883 | 0.070 |
Why?
|
Brain Ischemia | 1 | 2020 | 3001 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2022 | 3449 | 0.070 |
Why?
|
Sepsis | 1 | 2021 | 2605 | 0.070 |
Why?
|
Tuberculosis | 1 | 2020 | 2011 | 0.070 |
Why?
|
Education, Medical | 1 | 2018 | 1746 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4968 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26325 | 0.070 |
Why?
|
Reference Values | 2 | 2024 | 4918 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7469 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4357 | 0.060 |
Why?
|
Kidney | 1 | 2021 | 7063 | 0.060 |
Why?
|
Coronary Disease | 1 | 2020 | 5914 | 0.060 |
Why?
|
Students, Medical | 1 | 2018 | 1965 | 0.060 |
Why?
|
Menopause | 2 | 2024 | 1655 | 0.060 |
Why?
|
Aging | 1 | 2024 | 8729 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3253 | 0.060 |
Why?
|
Postmenopause | 2 | 2024 | 2518 | 0.060 |
Why?
|
Anticoagulants | 1 | 2019 | 4854 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5924 | 0.050 |
Why?
|
Utah | 1 | 2023 | 130 | 0.050 |
Why?
|
Child | 2 | 2023 | 80771 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8048 | 0.050 |
Why?
|
Time Factors | 1 | 2024 | 40154 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4859 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2022 | 16036 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3234 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5186 | 0.050 |
Why?
|
Young Adult | 4 | 2024 | 59980 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10869 | 0.050 |
Why?
|
Mutation | 1 | 2025 | 30211 | 0.040 |
Why?
|
Reproduction | 1 | 2024 | 646 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2022 | 475 | 0.040 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2024 | 562 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15645 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2021 | 531 | 0.040 |
Why?
|
Drug Resistance, Bacterial | 1 | 2024 | 1063 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21178 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2020 | 950 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2021 | 65295 | 0.030 |
Why?
|
Hepacivirus | 1 | 2022 | 1342 | 0.030 |
Why?
|
Adolescent | 1 | 2021 | 89046 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2024 | 3324 | 0.030 |
Why?
|
Acute Disease | 1 | 2023 | 7236 | 0.020 |
Why?
|
Dyspnea | 1 | 2020 | 1352 | 0.020 |
Why?
|
Risk | 1 | 2023 | 9606 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6844 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22350 | 0.020 |
Why?
|
Recurrence | 1 | 2023 | 8504 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2824 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15424 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18401 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54886 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10582 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4091 | 0.020 |
Why?
|
United States | 2 | 2024 | 72971 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12536 | 0.020 |
Why?
|
Disease Progression | 1 | 2020 | 13646 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11923 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 42606 | 0.010 |
Why?
|
Concepts
(229)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(18)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_